TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 616627928

Group type: EXPERIMENTAL
Intervention: Evidence-based asthma intervention (4 visits over 1 year)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 590
Study: 33878763

Group type: EXPERIMENTAL
Intervention: Algorithm A (exclusive consideration of carbohydrate content)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Algorithm B (high-dose algorithm considering additional insulin for fat protein units)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Algorithm C (low-dose algorithm considering additional insulin for fat protein units)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (not considering fat-protein content)
Number of subjects: 26
Study: 33232639

Group type: COMPARATOR
Intervention: MICT (5×30 min/week, 35%-50% HRR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 1HIIT (3×17 min/week incl. 4 min @80%-90% HRR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 4HIIT (3×38 min/week incl. 4×4 min @80%-90% HRR)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Entire group (all interventions combined)
Number of subjects: 29
Study: 32710447

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 38

Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 38
Study: 35933320

Group type: EXPERIMENTAL
Intervention: Anti-smoking intervention (ASI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no ASI)
Number of subjects: 72
Study: 34426836

Group type: EXPERIMENTAL
Intervention: AHRE duration >6 min to ≤6 h
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: AHRE duration >6 h
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: AHRE duration >6 min
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: AHRE duration >24 h
Number of subjects: 2718
Study: 35443062

Group type: EXPERIMENTAL
Intervention: Erlotinib with platinum-docetaxel
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo with platinum-docetaxel
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Erlotinib with chemotherapy
Number of subjects: 52
Study: 32631157

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 273

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Tenecteplase (after excluding stroke mimics)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Alteplase (after excluding stroke mimics)
Number of subjects: 273
Study: 32877244

Group type: EXPERIMENTAL
Intervention: PI-RADS category 2 lesions
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PI-RADS category 3 lesions
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PI-RADS category 4 lesions
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PI-RADS category 5 lesions
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PI-RADS category 1 lesions
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Normal multiparametric MRI findings (PI-RADS 1)
Number of subjects: 110
Study: 35542997

Group type: EXPERIMENTAL
Intervention: Piromelatine 20 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Piromelatine
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 32240527

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg every 2 weeks)
Number of subjects: 0
Study: 34231490

Group type: EXPERIMENTAL
Intervention: Long-term antithyroid drug therapy (LTADT; >24 months of treatment)
Number of subjects: 0
Study: 34737296

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 for 24 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Peg-IFN-α-2b therapy
Number of subjects: 130
Study: 32700060

Group type: COMPARATOR
Intervention: Digital human with no face and neutral voice
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Digital human with no face
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Digital human with no face and emotional voice
Number of subjects: 185

Group type: COMPARATOR
Intervention: Digital human with neutral face
Number of subjects: 185

Group type: COMPARATOR
Intervention: Digital human with emotional face
Number of subjects: 185
Study: 36027564

Group type: EXPERIMENTAL
Intervention: Mean arterial blood-pressure target of 77 mm Hg
Number of subjects: 789

Group type: COMPARATOR
Intervention: Mean arterial blood-pressure target of 63 mm Hg
Number of subjects: 789
Study: 33309875

Group type: EXPERIMENTAL
Intervention: Maze + LA reduction group (n=70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Maze group (n=70)
Number of subjects: 140
Study: 35318365

Group type: EXPERIMENTAL
Intervention: GWS + MIT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GWS + CIT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PUI + MIT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PUI + CIT
Number of subjects: 60
Study: 32122726

Group type: EXPERIMENTAL
Intervention: Primary closure of the extraction socket with a mucoperiosteal flap (group A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Application of platelet-rich fibrin (PRF) without subsequent primary closure (group B)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 77
Study: 34792531

Group type: EXPERIMENTAL
Intervention: 3 cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) before chemotherapy
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Stool incontinence assessment
Number of subjects: 311
Study: 33508240

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35101166

Group type: EXPERIMENTAL
Intervention: Team-based care (delegation of physicians' tasks to specialized rheumatological assistants)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Team-based care
Number of subjects: 601
Study: 34359567

Group type: EXPERIMENTAL
Intervention: Internet-based physical activity support program (IPAS)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: IPAS combined with physiotherapist telephone counselling (blended care)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study: 35365302

Group type: COMPARATOR
Intervention: Targeted Gene Panel Testing (TGPT) of 4 oncogenes (ALK, BRAF, EGFR, ROS1)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Comprehensive Genomic Profiling (CGP) of 10 oncogenes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1, NTRK2, NTRK3, RET, ROS1)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: No tumor profiling (no genes tested)
Number of subjects: 10000
Study: 32284058

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 56
Study: 33047321

Group type: EXPERIMENTAL
Intervention: Dietary intervention including marine omega-3 fatty acids, olive oil, and vitamin D
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo equivalents
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Healthier diet
Number of subjects: 55
Study: 33129376

Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg per day orally) plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 33740110

Group type: EXPERIMENTAL
Intervention: Tourniquet at low pressures (100 mmHg above systolic blood pressure)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No tourniquet (Control group)
Number of subjects: 71
Study: 33438529

Group type: EXPERIMENTAL
Intervention: 3DIZI-guided injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ultrasound-guided injections
Number of subjects: 0
Study: 32565133

Group type: EXPERIMENTAL
Intervention: Vinflunine plus Best Supportive Care (VFL + BSC)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 87
Study: 35915405

Group type: EXPERIMENTAL
Intervention: STROKE-CARD care
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2149
Study: 33754755

Group type: EXPERIMENTAL
Intervention: Reservoir Computing (RC) with linear activation and quadratic readout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reservoir Computing (RC) with identity activation function
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vector Autoregressive (VAR) models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic Mode Decomposition (DMD)
Number of subjects: 0
Study: 2004928420

Group type: EXPERIMENTAL
Intervention: Real tDCS/Real tACS (ACDC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS/Real tACS (AC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS/Sham tACS (Sham)
Number of subjects: 24
Study: 35329279

Group type: EXPERIMENTAL
Intervention: Proprioception training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Routine conservative physiotherapy treatment
Number of subjects: 45
Study: 33817894

Group type: EXPERIMENTAL
Intervention: Narrative therapy in addition to standard care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 32148255

Group type: EXPERIMENTAL
Intervention: Recycled water
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Reclaimed water
Number of subjects: 1264
Study: 34331996

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34755389

Group type: EXPERIMENTAL
Intervention: 500 ml of semi‐skimmed milk containing approximately 600 mg of calcium with 200 µg of cholecalciferol
Number of subjects: 20

Group type: COMPARATOR
Intervention: 500 ml of water with 200 µg of cholecalciferol
Number of subjects: 20
Study: 36196926

Group type: EXPERIMENTAL
Intervention: weCare intervention (n = 100)
Number of subjects: 198

Group type: COMPARATOR
Intervention: usual-care (n = 98)
Number of subjects: 198
Study: 32885875

Group type: EXPERIMENTAL
Intervention: Dual-focus (DF) contact lens
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single-vision (SV) contact lens
Number of subjects: 28
Study: 35246030

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus dose, followed by a 2 mg/kg/h continuous infusion)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 36410561

Group type: EXPERIMENTAL
Intervention: Dietary Modification (low-fat diet with increased vegetable, fruit, and grain intake)
Number of subjects: 23217

Group type: COMPARATOR
Intervention: Usual diet without modification (Control)
Number of subjects: 23217
Study: 34650833

Group type: EXPERIMENTAL
Intervention: High Dose Aldesleukin (HD rIL-2) followed by Ipilimumab (IPI)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HD rIL-2 followed by IPI
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: IPI followed by HD rIL-2
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both arms (HD rIL-2 and IPI)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HD rIL-2
Number of subjects: 29
Study: 33174437

Group type: EXPERIMENTAL
Intervention: Village health workers (VHWs) in rural communities
Number of subjects: 429

Group type: COMPARATOR
Intervention: Urban VHWs
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Rural VHWs
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Training of VHWs
Number of subjects: 429
Study: 36097694

Group type: EXPERIMENTAL
Intervention: Posterolateral approach
Number of subjects: 555

Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 555
Study: 34882062

Group type: EXPERIMENTAL
Intervention: Psychological factors (personality factors, symptoms of depression and anxiety, perceived stress)
Number of subjects: 1219
Study: 32362168

Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Dietary advice combined with oral nutritional supplements
Number of subjects: 671

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 671
Study: 36263240

Group type: EXPERIMENTAL
Intervention: Nonsurgical spinal decompression therapy (NSDT), performed ten times in eight weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nonsurgical spinal decompression therapy (NSDT)
Number of subjects: 60
Study: 33598937

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (bMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational session on breastfeeding (control)
Number of subjects: 0
Study: 33302782

Group type: EXPERIMENTAL
Intervention: Attend to Source Instructions
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control Instructions
Number of subjects: 102
Study: 32565480

Group type: EXPERIMENTAL
Intervention: Intraoperative irrigation and subdural drainage
Number of subjects: 540

Group type: COMPARATOR
Intervention: No intraoperative irrigation and subdural drainage
Number of subjects: 540
Study: 32418302

Group type: EXPERIMENTAL
Intervention: Learning Algorithm (LA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Physician Adjustments (PA)
Number of subjects: 21
Study: 33516710

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol titrated to 0.08% blood alcohol concentration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (volume and osmolarity-matched, masked)
Number of subjects: 100
Study: 32268554

Group type: COMPARATOR
Intervention: Control drink (2 kcal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: P280 (70 g protein, 0 g fat, 0 g carbohydrate, 280 kcal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: M280 (14 g protein, 12.4 g fat, 28 g carbohydrate, 280 kcal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: M504 (70 g protein, 12.4 g fat, 28 g carbohydrate, 504 kcal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Caloric drinks
Number of subjects: 26
Study: 32721228

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sotagliflozin (200 mg and 400 mg combined)
Number of subjects: 100
Study: 32609653

Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Number of subjects: 50
Study: 34342122

Group type: EXPERIMENTAL
Intervention: Proposed method for interval estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real data on adverse events in a clinical trial
Number of subjects: 0
Study: 34049835

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 50

Group type: COMPARATOR
Intervention: Orthokin mouthwash
Number of subjects: 50
Study: 35709728

Group type: EXPERIMENTAL
Intervention: Routine gastric residual aspiration
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nonroutine gastric residual aspiration
Number of subjects: 51
Study: 34240282

Group type: EXPERIMENTAL
Intervention: 4-months multi-component exercise program (28 sessions of strength and balance exercises)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 378
Study: 32164882

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 12844

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 12844
Study: 34822741

Group type: EXPERIMENTAL
Intervention: PACAP38 (10 pmol/kg/min)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (8 pmol/kg/min)
Number of subjects: 44
Study: 34264994

Group type: EXPERIMENTAL
Intervention: Elamipretide (ELAM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 35487526

Group type: EXPERIMENTAL
Intervention: Escalated dose radiotherapy (62 Gy to primary tumour, 50.4 Gy to surrounding mesorectum in 28 fractions) with concurrent chemotherapy (capecitabine, 5-fluorouracil/leucovorin or omitted)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 50.4 Gy to the primary tumour and surrounding mesorectum with concurrent chemotherapy (capecitabine, 5-fluorouracil/leucovorin or omitted)
Number of subjects: 104
Study: 34965712

Group type: EXPERIMENTAL
Intervention: Rehabilitation complex including therapeutic exercises, mechanotherapy, electrical stimulation, gravitational therapy, and antiresorptive therapy (10 procedures)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rehabilitation complex including therapeutic exercises, mechanotherapy, electrical stimulation (10 procedures)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rehabilitation complex including gravitational therapy and antiresorptive therapy
Number of subjects: 40
Study: 33316689

Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg/day, target trough level: 4-6 ng/mL) for six months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 10
Study: 32301225

Group type: EXPERIMENTAL
Intervention: Pancreas and kidney transplantation
Number of subjects: 43
Study: 35680613

Group type: EXPERIMENTAL
Intervention: GI Genius™-assisted colonoscopy (GGC)
Number of subjects: 1828

Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC)
Number of subjects: 1828
Study: 34002558

Group type: EXPERIMENTAL
Intervention: Abdominal penetrating moxibustion, approximately 50 min each time, once a day, for 4 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine basic treatment, acupuncture treatment, and rehabilitation training
Number of subjects: 62
Study: 35232310

Group type: EXPERIMENTAL
Intervention: No compression
Number of subjects: 104

Group type: COMPARATOR
Intervention: Compression (class II thigh-high)
Number of subjects: 104
Study: 32100917

Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 153
Study: 35538329

Group type: EXPERIMENTAL
Intervention: Occlusal splint (OS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No device (reference night)
Number of subjects: 21
Study: 36328113

Group type: EXPERIMENTAL
Intervention: Screening with implantable loop recorder (ILR) and subsequent anticoagulation upon detection of new-onset AF episodes ≥6 min
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1997
Study: 32052567

Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Psychoeducation group
Number of subjects: 16
Study: 32511143

Group type: COMPARATOR
Intervention: Control group received infiltration of 0.5% bupivacaine 100 mg (20 mL) and epinephrine 0.5 mg (0.5 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multimodal group received infiltration with 0.5% bupivacaine 92.5 mg (18.5 mL), ketorolac 30 mg (1 mL), morphine 5 mg (0.5 mL), and epinephrine 0.5 mg (0.5 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multimodal group
Number of subjects: 80
Study: 35168972

Group type: EXPERIMENTAL
Intervention: Mindful Living with Insomnia (MLWI)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Number of subjects: 250
Study: 33779579

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 1072
Study: 32296223

Group type: EXPERIMENTAL
Intervention: McConnell taping combined with strengthening exercises of vastus medialis oblique muscle
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 35140342

Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus cisplatin-radiation (NCRT)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Cisplatin-radiation (CRT)
Number of subjects: 404
Study: 34711224

Group type: EXPERIMENTAL
Intervention: Relugolix 10 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Relugolix 20 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Relugolix 40 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 34351426

Group type: EXPERIMENTAL
Intervention: β‐blocker therapy (agent and dose according to treating physician)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No β‐blocker therapy
Number of subjects: 0
Study: 32954412

Group type: EXPERIMENTAL
Intervention: blue‐depleted light environment
Number of subjects: 12

Group type: COMPARATOR
Intervention: normal lighting
Number of subjects: 12
Study: 32157626

Group type: EXPERIMENTAL
Intervention: LAN new syringe
Number of subjects: 90

Group type: COMPARATOR
Intervention: octreotide LAR syringe
Number of subjects: 90
Study: 35910893

Group type: EXPERIMENTAL
Intervention: Smartphone ZTEx intervention (15-min face-to-face session + 12-week ZTEx instant messaging with 28 picture e-messages and ZTExApp)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (same duration of individual session and number and format of e-messages, but content was healthy eating and breathing exercise)
Number of subjects: 139
Study: 32985108

Group type: EXPERIMENTAL
Intervention: Low-fat meal (20% fat, 60% carbohydrate, 20% protein; FQ = 0.899)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-fat meal (60% fat, 20% carbohydrate, 20% protein; FQ = 0.784)
Number of subjects: 8
Study: 35927732

Group type: EXPERIMENTAL
Intervention: Web-based decision support tools for chemoprevention
Number of subjects: 7
Study: 35189589

Group type: EXPERIMENTAL
Intervention: MFG-PP (Multiple Family Group - Parent Peers)
Number of subjects: 2391

Group type: EXPERIMENTAL
Intervention: MFG-CHW (Multiple Family Group - Community Health Workers)
Number of subjects: 2391

Group type: COMPARATOR
Intervention: Comparison with other family-based interventions
Number of subjects: 2391
Study: 33793040

Group type: COMPARATOR
Intervention: Artificially reduced depth of penetration using silicone rings around the base of the man's erect penis.
Number of subjects: 12